| Name | Title | Contact Details |
|---|
Homecare America is a Jupiter, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Allied Benefit Systems is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DispatchHealth is redefining healthcare delivery through the most advanced on-demand, in-home healthcare model in the country. Our board-certified medical teams can treat common to complex injuries and illnesses in the comfort of your home.
inVentiv Health, Inc. provides value-added services to the pharmaceutical, life sciences, and healthcare industries. The Company operates in four segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. The Company supports a range of clinical development, communications and commercialization activities that are critical to its customers' ability to complete the development of drug products and medical devices and commercialize them. In addition, the Company provides medical cost containment services to payors in its patient outcomes business. inVentiv provides services to over 350 client organizations, including global pharmaceutical companies, emerging and specialty biotechnology companies, and payors.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.